Rosalind Advisors Inc. Has $885,000 Stock Position in Biofrontera Inc. (NASDAQ:BFRI)

Rosalind Advisors Inc. raised its holdings in shares of Biofrontera Inc. (NASDAQ:BFRIFree Report) by 63.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 811,918 shares of the company’s stock after acquiring an additional 316,428 shares during the quarter. Biofrontera makes up 0.4% of Rosalind Advisors Inc.’s portfolio, making the stock its 25th biggest position. Rosalind Advisors Inc. owned 0.10% of Biofrontera worth $885,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, AIGH Capital Management LLC grew its stake in shares of Biofrontera by 61.8% during the fourth quarter. AIGH Capital Management LLC now owns 811,097 shares of the company’s stock worth $884,000 after purchasing an additional 309,663 shares during the period. 10.08% of the stock is owned by institutional investors.

Biofrontera Trading Down 16.5 %

NASDAQ BFRI opened at $0.86 on Friday. Biofrontera Inc. has a 12 month low of $0.65 and a 12 month high of $2.43. The company has a market capitalization of $6.66 million, a PE ratio of -0.38 and a beta of 0.30. The stock has a 50-day simple moving average of $1.04 and a 200 day simple moving average of $1.03.

About Biofrontera

(Free Report)

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.

Recommended Stories

Want to see what other hedge funds are holding BFRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biofrontera Inc. (NASDAQ:BFRIFree Report).

Institutional Ownership by Quarter for Biofrontera (NASDAQ:BFRI)

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.